Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03477058
Other study ID # LPC-17/2016
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 23, 2017
Est. completion date February 6, 2017

Study information

Verified date December 2023
Source Dr. August Wolff GmbH & Co. KG Arzneimittel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to evaluate the cosmetic features of the product WO 3308 by means of a questionnaire in an interview situation after two weeks of product treatment, giving special consideration to the cosmetic performance, efficacy and skin compatibility and with special focus on the reduction of pruritus. Additionally the tolerance will be evaluated by a dermatologist.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date February 6, 2017
Est. primary completion date February 6, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - age: = 18 years - sex: approx. 25% to 50% male and 50% to 75% female - with acute pruritus (lasts less than 6 weeks) or chronic pruritus (lasts longer than 6 weeks): max. 50% with acute pruritus and at least 50% with chronic pruritus Exclusion Criteria: - any deviation from the above-mentioned criteria - known incompatibilities to cosmetics and ingredients of cosmetic test products (please see INCI) - topical medication in the test area within 1 month prior to study start - systemic medication with antibiotics within 2 weeks prior to starting of the study - change in the medication with anti-inflammatory agents within 2 weeks prior to starting the study - systemic medication with immunomodulators (immunsuppressive drugs in the course of a transplantation) and/or chemotherapeutic agents within 4 weeks prior to starting the study - neurodermatitis (atopic dermatitis) - pregnancy and period of breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Other:
WO 3308 cosmetic product for topical use
Application on the entire body at least once a day over two weeks

Locations

Country Name City State
Germany SIT Skin Investigation and Technology Hamburg GmbH Hamburg

Sponsors (2)

Lead Sponsor Collaborator
Dr. August Wolff GmbH & Co. KG Arzneimittel SIT Skin Investigation and Technology Hamburg GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cosmetic Features of the Test Product Change from baseline for the cosmetic features (spreadability, absorbtion, skin feeling after application, fragrance) of the test product by the means of an interview-based questionnaire baseline, two weeks
Primary Reduction of Pruritus Change from baseline reduction of pruritus at two weeks by the means of an interview-based questionnaire baseline, two weeks
Secondary Tolerance of the Test Product on the skin Change from baseline at two weeks by the means of a dermatological and subjective assessment of skin tolerance on arms and legs baseline, two weeks
See also
  Status Clinical Trial Phase
Completed NCT05038982 - Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin Phase 2
Completed NCT04510090 - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus Phase 1
Completed NCT02143973 - Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus Phase 2/Phase 3
Terminated NCT01825655 - Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching Phase 4
Completed NCT01236859 - Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus N/A
Completed NCT00782054 - Evaluation of Post Burn Rehabilitation Population for Itch Control Phase 4
Completed NCT04999787 - A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus Phase 2
Recruiting NCT04256759 - Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus Phase 2
Completed NCT04337073 - The Effect of Propofol on Dexamethasone-induced Perineal Pruritus Early Phase 1
Completed NCT04415034 - Scalp Pruritus Measurement Using Visual Analog Scale and 5-d Itch Scale in Children With Pediculosis Capitis
Active, not recruiting NCT05525520 - Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis Phase 2
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Completed NCT04399525 - Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin. N/A
Recruiting NCT02432508 - Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis N/A
Completed NCT02653703 - L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain N/A
Completed NCT01963793 - Topical Aprepitant in Prurigo Patients Phase 2
Completed NCT01232985 - Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults Phase 2
Not yet recruiting NCT00577967 - Gabapentin - A Solution to Uremic Pruritus? N/A
Recruiting NCT06120907 - Swiss Itch Registry
Recruiting NCT04589429 - Adding Nalbuphine for Control of Intrathecal Morphine Pruritus Phase 2